Details

Autor(en) / Beteiligte

• Ali, Nidhal
• Sebastian, Cherry
• Foley, Rosemary R
• Murray, Iain
• Canizales, Ana L
• Jenkins, Paul J
• Drake, William M
• Nicholas Plowman, P
• Michael Besser, G
• Chew, Shern L
• Grossman, Ashley B
• Monson, John P
• Britton, Keith E

Titel

The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy

Ist Teil von

• Nuclear medicine communications, 2006-02, Vol.27 (2), p.165-169

Ort / Verlag

England: Lippincott Williams & Wilkins, Inc

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• BACKGROUNDFollow-up of I whole-body scanning after I ablation is associated with potential stunning. Previous studies have suggested that, for scanning, I is more sensitive than I in identifying thyroid tissue, but its specificity when positive is less certain. AIMThe use of I as an imaging agent in place of serial I imaging has been evaluated in the surveillance and treatment of differentiated thyroid carcinoma. RESULTSA total of 186 studies in 136 patients with differentiated thyroid carcinoma were evaluated after total or near total thyroidectomy followed by I ablation. In 125 studies I scanning was negative and no I therapy was given; four patients were positive on I scanning but for other reasons no I therapy was given. In 48/49 patients a positive I scan was followed by positive I therapeutic uptake. Only one patient failed to show positive uptake of I when first treated and she subsequently demonstrated uptake on a second therapy. CONCLUSIONHigh-dose I imaging is the correct predictor of the I post-therapy scan findings in most cases, at an administered activity that avoids stunning. As a diagnostic agent it is preferable to I in differentiated thyroid carcinoma.